Beryl Drugs reports Q2 profit despite facility suspension, upgrade

Beryl Drugs Limited reported a profit before tax of INR 26.03 lacs for the quarter ended September 30, 2025, with total income reaching INR 515.66 lacs. This compares to a profit before tax of INR 6.97 lacs in the previous quarter and INR 10.77 lacs in the corresponding quarter of the previous year. The profit after tax for the current quarter stood at INR 0.89 lacs.

The company's cash flow from operating activities showed a net cash used of INR 215.71 lacs for the six months ended September 30, 2025. Investing activities resulted in a net cash used of INR -295.14 lacs, primarily due to purchases of property, plant, and equipment totaling INR -301.82 lacs.

Beryl Drugs noted that a portion of its manufacturing facility is currently suspended and undergoing upgrades as per a state FDA order. While a rectification/compliance statement has been submitted, production has not yet recommenced, awaiting inspection by the Food and Drugs Administration.